


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A C-Glycosylisoflavone compound of the formula (I) having alkylaminoalkoxyl substituent or a pharmaceutically acceptable salt thereof:



wherein, R₁ and R₂ are independently selected from the group consisting of hydrogen, (C₁-C₁₂) linear or branched alkylamino (C₁-C₆)alkyl, mono- or di-(C₃₋₈)cycloalkylamino-C₁₋₆alkyl, [[or]]and (C₅-C₁₄)heterocyclic-(C₁-C₆)alkyl; R₃ is selected from the group consisting of hydrogen, (C₁-C₁₂) linear or branched acyl[[, or]] and C₆₋₁₄ aryl carbonyl; wherein R₁ and R₂ do

Appln No. 10/563,471

Amdt date September 21, 2009

Reply to Office action of March 19, 2009

not represent hydrogen simultaneously; the 1-position of D-glucosyl is connected with the 8-position of the isoflavone in a form of β -configured C-glycoside, wherein the mono- or di-(C₃₋₈)cycloalkylamino group of the mono- or di-(C₃₋₈)cycloalkylamino-C₁₋₆alkyl includes pyrrolidinyl and morpholinyl, and the (C₅-C₁₄)heterocyclic group of the (C₅-C₁₄)heterocyclic-(C₁-C₆)alkyl is selected from the group consisting of piperidyl, piperazinyl, N-methylpiperazinyl, and N-ethylpiperazinyl.

2. (Currently Amended) The compound according to claim 1, characterized in that in formula [(2)] (I), R₁ and R₂ are independently selected from the group consisting of hydrogen, dimethylaminoethyl, diethylaminoethyl, di(n-propyl)aminoethyl, di(iso-propyl)aminoethyl, di(n-butyl)aminoethyl, di(iso-butyl)aminoethyl, di(tert-butyl)aminoethyl, pyrrolidinylethyl, piperidylethyl, morpholinylethyl, piperazinylethyl, N-methylpiperazinylethyl, N-ethylpiperazinylethyl, tert-butylaminoethyl, dicyclohexylaminoethyl, dimethylaminopropyl, diethylaminopropyl, di(n-propyl)aminopropyl, di(iso-propyl)aminopropyl, di(n-butyl)aminopropyl, di(iso-butyl)aminopropyl, di(tert-butyl)aminopropyl, pyrrolidinylpropyl, piperidylpropyl, morpholinylpropyl, piperazinylpropyl, N-methylpiperazinylpropyl, N-ethylpiperazinylpropyl, tert-butylaminopropyl, dicyclohexylaminopropyl, dimethylaminobutyl, diethylaminobutyl, di(n-propyl)aminobutyl, di(iso-propyl)aminobutyl, di(n-butyl)aminobutyl, di(iso-butyl)aminobutyl, di(tert-butyl)aminobutyl, pyrrolidinylbutyl, piperidylbutyl, morpholinylbutyl, piperazinylbutyl, N-methylpiperazinylbutyl, N-ethylpiperazinylbutyl, tert-butylaminobutyl, and dicyclohexylaminobutyl, wherein R₁ and R₂ do not represent hydrogen simultaneously; R₃ is selected from the group consisting of hydrogen, propionyl, butyryl, isobutyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethylpropionyl, valeryl, caproyl, heptanoyl, octanoyl, nonanoyl, decanoyl, and lauroyl; [[or a]] and wherein the pharmaceutically acceptable salt is selected from the group consisting of [[the]] salts of hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, sulfuric acid, methane sulfonic acid, p-toluene sulfonic acid, maleic acid, fumaric acid, tartaric acid, and various natural or non-natural amino acids.

Appln No. 10/563,471

Amdt date September 21, 2009

Reply to Office action of March 19, 2009

3. (Currently Amended) The compound according to claim 1, wherein the compound of the formula (I) is selected from the group consisting of:

4'-(3-N-piperidylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(3-N-morpholinylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(3-N-pyrrolidinylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(3-diethylaminopropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-[3-di(n-propyl)aminopropoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

4'-[3-di(n-butyl)aminopropoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

4'-[3-(4-methylpiperazinyl)propoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

4'-[3-(4-ethylpiperazinyl)propoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

4'-(4-N-piperidylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(4-N-morpholinylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(4-N-pyrrolidinylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(4-diethylaminobutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone,

4'-(4-di(n-propyl)aminobutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)- isoflavone,

4'-(4-di(n-butyl)aminobutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

4'-[4-(4-methylpiperazinyl)butoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

4'-[4-(4-ethylpiperazinyl)butoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)

isoflavone,

[[or]] and a pharmaceutically acceptable salt thereof.

Appln No. 10/563,471
Amdt date September 21, 2009
Reply to Office action of March 19, 2009

4. (Currently Amended) A pharmaceutical composition comprising [[a]] the C-Glycosylisoflavone compound of claim 1 and a pharmaceutically acceptable carrier.
5. (Currently amended) A preparation method of [[a]] the C-Glycosylisoflavone compound of claim 1, characterized in comprising, reacting puerarin material with a corresponding suitable bis-functional group substituted compound such as a bihalogenated hydrocarbon, an alkylene bissulfonate, or a halogenated hydrocarbon monosulfonate etc., in a suitable solvent selected from water, acetone, dimethylformamide, dimethyl sulfoxide, and lower alcohols, under the presence of a base, an ambient to reflux- temperature, which is firstly mono-etherified followed by amination and/or salt-formation, to give the corresponding alkylaminoalkoxyl-substituted C-Glycosylisoflavone compound or a pharmaceutically acceptable salt thereof.
6. (Currently amended) ~~Use of a compound of claim 1 in the manufacture of a medicament~~
A method for [[the]] treatment of cardio- and cerebrovascular diseases as well as a medicament for the treatment of hypoxia or ischemia, comprising administering a therapeutically effective amount of the C-Glycosylisoflavone compound of claim 1 to a patient in need.
7. (Currently amended) ~~Use of a compound of claim 1 in the manufacture of a medicament~~
A method for [[the]] treatment of diabetes as well as diabetic complications, comprising administering a therapeutically effective amount of the C-Glycosylisoflavone compound of claim 1 to a patient in need.
8. (Currently amended) ~~Use of a compound of claim 1 in the manufacture of a medicament~~
A method for [[the]] treatment of chemical poisoning, particularly alcoholism, comprising administering a therapeutically effective amount of the C-Glycosylisoflavone compound of claim 1 to a patient in need.
9. (New) The preparation method as set forth in claim 5, wherein said bis-functional group substituted compound is selected from the group consisting of a bihalogenated hydrocarbon, an alkylene bissulfonate, and a halogenated hydrocarbon monosulfonate.

Appln No. 10/563,471

Amdt date September 21, 2009

Reply to Office action of March 19, 2009

10. (New) The method as set forth in claim 8, wherein said chemical poisoning is alcohol poisoning.